Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Assessment, 2022 – Emerging Drugs, Latest FDA and EMA Approvals, Clinical Trials | Aura Biosciences (belzupacap sarotalocan (AU-011)), ImmunityBio

Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Assessment, 2022 - Emerging Drugs, Latest FDA and EMA Approvals, Clinical Trials | Aura Biosciences (belzupacap sarotalocan (AU-011)), ImmunityBio
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the Non-Muscle Invasive Bladder Cancer (NMIBC) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Non-Muscle Invasive Bladder Cancer Market. 

The Non-Muscle Invasive Bladder Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Non-Muscle Invasive Bladder Cancer Pipeline Analysis

Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Non-Muscle Invasive Bladder Cancer and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Muscle Invasive Bladder Cancer Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Non-Muscle Invasive Bladder Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Latest Developments in the Non-Muscle Invasive Bladder Cancer (NMIBC) Therapeutics Market –

On September 28, 2022, Aura Biosciences Inc. (NASDAQ: AURA) announced that the first patient had been dosed in a Phase 1 study evaluating belzupacap sarotalocan (AU-011). Belzupacap sarotalocan is Aura Biosciences’s first VDC product candidate for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

On July 28, 2022, the FDA accepted to review ImmunityBio’s (NASDAQ: IBRX) Biologics License Application (BLA) for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.

Learn How the Ongoing Clinical & Commercial Activities will Affect the Non-Muscle Invasive Bladder Cancer Therapeutic Segment:

Non-Muscle Invasive Bladder Cancer (NMIBC) Therapeutics Landscape

There are approx. 30+ key companies which are developing therapies for Non-Muscle Invasive Bladder Cancer. Currently, UroGen Pharma has its Non-Muscle Invasive Bladder Cancer drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Non-Muscle Invasive Bladder Cancer (NMIBC) Therapeutics Market include:

Merck, Theralase, Altor Biosciences, ImmunityBio, Ferring Pharmaceuticals, FKD Therapies Oy, Viventia Bio, UroGen Pharma, CG Oncology, Sasanlimab, Sesen Bio, Theralase Technologies, Asieris Pharmaceuticals, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, Vaxiion Therapeutics, Janssen Pharmaceuticals, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Incyte Corporation, Taizhou Hanzhong biomedical, and others

Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs Covered in the report include:

• UGN-102

• Sasanlimab

• Vicinium

• Adstiladrin

• CG0070

• N-803 (ALT-803)

• TLD-1433

• Keytruda

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Non-Muscle Invasive Bladder Cancer Current Treatment Patterns

4. Non-Muscle Invasive Bladder Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Non-Muscle Invasive Bladder Cancer Late Stage Products (Phase-III)

7. Non-Muscle Invasive Bladder Cancer Mid-Stage Products (Phase-II)

8. Non-Muscle Invasive Bladder Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Muscle Invasive Bladder Cancer Discontinued Products

13. Non-Muscle Invasive Bladder Cancer Product Profiles

14. Key Companies in the Non-Muscle Invasive Bladder Cancer Market

15. Key Products in the Non-Muscle Invasive Bladder Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Non-Muscle Invasive Bladder Cancer Unmet Needs

18. Non-Muscle Invasive Bladder Cancer Future Perspectives

19. Non-Muscle Invasive Bladder Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Diabetic Eye Disease Market

“Diabetic Eye Disease Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Diabetic Eye Disease Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States